IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
Outcomes for patients diagnosed with the bone cancer osteosarcoma have not improved significantly in the last four decades. Only around 60% of patients and about a quarter of those with metastatic disease survive for more than five years. Although DNA-damaging chemotherapy drugs can be effective, th...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Impact Journals LLC
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085125/ |